Literature DB >> 26549392

Mid-Term Administration of Tolvaptan Improves Renal Function Accompanied by Dose-Reduction in Furosemide in Aquaporin-Defined Responders.

Teruhiko Imamura1, Koichiro Kinugawa.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26549392     DOI: 10.1536/ihj.15-298

Source DB:  PubMed          Journal:  Int Heart J        ISSN: 1349-2365            Impact factor:   1.862


× No keyword cloud information.
  1 in total

Review 1.  Urine Aquaporin-2: A Promising Marker of Response to the Arginine Vasopressin Type-2 Antagonist, Tolvaptan in Patients with Congestive Heart Failure.

Authors:  Teruhiko Imamura; Koichiro Kinugawa
Journal:  Int J Mol Sci       Date:  2016-01-14       Impact factor: 5.923

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.